Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial

International Journal of Clinical Oncology

Volumn 18, Issue 3, 2013, Pages 472-477

  Uemura, Hiroji ^a   Yanagisawa, Masahiro ^b   Ikeda, Ichirou ^b   Fujinami, Kiyoshi ^c   Iwasaki, Akira ^d   Noguchi, Sumio ^e   Noguchi, Kazumi ^f   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c Chigasaki City Hospital   (Japan)

^d YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^e YOKOSUKA KYOSAI HOSPITAL   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Anti tumor activity; Bone metastasis; Maximal androgen blockade; Prostate cancer; Zoledronic acid

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84879414902     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0406-8     Document Type: Article

References (24)

1. Cooperberg MR, Hinotsu S, Namiki M et al (2009) Assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27:4306-4313
2. Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240
3. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
4. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
5. Demers LM (2003) Bone markers in the management of patients with skeletal metastases. Cancer 97(3 Suppl):874-879
6. Percival RC, Urwin GH, Harris S et al (1987) Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13:41-49
7. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
8. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420-432
9. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
10. Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194
11. Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195-202
12. DePuy V, Anstrom KJ, Castel LD et al (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869-876
13. Yigitbasi O, Ozturk U, Goktug HN et al (2011) Prognostic factors in metastatic prostate cancer. Urol Oncol 29:162-165
14. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
15. Velde NV, Wu EQ, Guo A et al (2011) The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis 14:79-84
16. Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475
17. Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144-151
18. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572-583
19. Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175-1181
20. Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010
21. Coleman R, Cook R, Hirsh V et al (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11-23
22. Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13(15 Pt 1):4482-4486
23. Melisi D, Caputo R, Damiano V et al (2005) Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12:1051-1058
24. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA et al (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371